Home Contact
Login   |  Tell a Friend
Financial Optimization through Technology Innovation
mutual fund
 Top Fund Managers
Latest Mutual Fund News Latest Mutual Fund News

Financial Advisor Sponsor:Dean L. Boebinger


 Bookmark this site!
Follow FundMojo on Twitter
Get Fund Information

Get Stock News

(Enter Stock Symbol)

Partner Sites

Annuities
Wall Street Journal
eHealthInsurance
Fund Mojo on Facebook
Fund Mojo help you discover the best fund managers, funds, and related information

Fund Intelligence | Best Managers | JAGLX Insights | JAGLX Score | JAGLX Performance | JAGLX Manager | JAGLX News | JAGLX Allocation | JAGLX Holdings Change

Mutual Fund Insights: Janus Global Life Sciences J Fund (JAGLX)

In-depth Analysis of Janus Global Life Sciences J Fund (JAGLX)

Mutual fund chart: Janus Global Life Sciences J Fund (JAGLX)

3 months
6 months
1 year
3 year
5 year

See Janus Global Life Sciences J Fund (JAGLX) performance details as of January 31, 2010

  

    Last Trade: $22.66 on 3/19/2010, Change: -0.03 (-0.13%)

  

Fund Manager - Andrew Acker

Fund Manager Tenure: 2.9 years
Fundmojo Fund Grade: B (Score: 0.6)     (What does this score mean?)
Acker joined Janus Capital in 1999 as a securities analyst. He is a portfolio manager at the firm. Acker holds the Chartered Financial Analyst designation.  Get more insights on Andrew Acker

  

What we like about Janus Global Life Sciences J Fund (JAGLX) What we like about Janus Global Life Sciences J Fund (JAGLX)

Data for Janus Global Life Sciences J Fund (JAGLX) as of January 31, 2010

  • Janus Global Life Sciences J Fund (JAGLX) has good short-term performance (1-year return 25.53% vs 24.07% Health category average)
  • Janus Global Life Sciences J Fund (JAGLX) has good mid-term performance (3-year return 2.25% vs -0.24% Health category average)
  • Janus Global Life Sciences J Fund (JAGLX) has good Long-term performance (5-year return 4.51% vs 4.22% Health category average)
  • Janus Global Life Sciences J Fund (JAGLX) has an annual stock turnover rate of 70.00% vs Health average of 152.72%. It is good that Janus Global Life Sciences J management does not trade extensively for its return.
  • Janus Global Life Sciences J Fund (JAGLX) is less volatile than its peers as it has a 3-year Standard Deviation of 18.27, lower than category average of 18.84
  • Janus Global Life Sciences J Fund (JAGLX) has a lower management fee than its Health average: 0.98% vs 1.91%
  • Janus Global Life Sciences J Fund (JAGLX) is a true no-load fund as it has no load and no 12b1 promotion, distributions, marketing expenses

  

What we are cautious about Janus Global Life Sciences J Fund (JAGLX) What we are cautious about Janus Global Life Sciences J Fund (JAGLX)

Data for Janus Global Life Sciences J Fund (JAGLX) as of January 31, 2010

  • Janus Global Life Sciences J Fund (JAGLX) management has been with Janus Global Life Sciences J Fund for only 2.9 years, it is hard to judge manager's ability based on this fund's operation record
  • Janus Global Life Sciences J Fund is a focused fund with 30.93% of the portfolio on top 10 securities. This tends to produce more volatility compared to a diversified fund. See fund top 10 holdings.
  • Janus Global Life Sciences J Fund (JAGLX) ratio of up-years vs down years can be improved
  • Janus Global Life Sciences J Fund (JAGLX) has a Morningstar rating of 3 and below
  • Janus Global Life Sciences J Fund (JAGLX) is less safe compared to its Health peers
See Janus Global Life Sciences J Fund (JAGLX) performance details as of January 31, 2010

  

  

Interested in other top mutual funds in similar Health category?

Below are some additional Health mutual funds generated out of our database

  

Janus Global Life Sciences J Fund (JAGLX) Net Asset

Track net asset change of Janus Global Life Sciences J fund (JAGLX)

DateNet Asset
01/2010$696.42M
11/2009$681.05M
10/2009$677.07M
More historic net asset information on Janus Global Life Sciences J Fund (JAGLX)

  

Janus Global Life Sciences J Fund (JAGLX) Portfolio Allocation

Track portfolio allocation change of Janus Global Life Sciences J fund (JAGLX)

DateCashStockBondOther
09/20091.19%96.5%0%2.3%
06/20090.72%97.09%0%2.19%
03/20094.77%91.98%0%3.25%
Click here to see more historic asset allocation information on Janus Global Life Sciences J Fund (JAGLX)

  

Most Recent Top 10 Holdings in Janus Global Life Sciences J Fund (JAGLX)

Discover what Janus Global Life Sciences J Fund (JAGLX) manager is buying

30-Sep-09
Celgene Corporation [4%]
Roche Holding AG [3.91%]
MERCK CO INC [3.38%]
Gilead Sciences, Inc. [3.25%]
Genzyme Corporation [3.25%]
WYETH [3.17%]
CVS CAREMARK CP [2.94%]
Alexion Pharmaceuticals, Inc. [2.59%]
ABBOTT LABORATORIES [2.56%]
ASTRAZENECA PLC ADS [2.37%]

30-Jun-09
Celgene Corporation [4%]
Roche Holding AG [3.91%]
MERCK CO INC [3.38%]
Gilead Sciences, Inc. [3.25%]
Genzyme Corporation [3.25%]
WYETH [3.17%]
CVS CAREMARK CP [2.94%]
Alexion Pharmaceuticals, Inc. [2.59%]
ABBOTT LABORATORIES [2.56%]
ASTRAZENECA PLC ADS [2.37%]

31-Mar-09
Roche Holding AG [4.87%]
Gilead Sciences, Inc. [3.56%]
Celgene Corporation [3.3%]
CVS CAREMARK CP [3.27%]
WYETH [3.21%]
MERCK CO INC [3.21%]
Genzyme Corporation [2.74%]
Bayer AG [2.6%]
ASTRAZENECA PLC ADS [2.42%]
UNITEDHEALTH GROUP [2.41%]
Click here for Stock Holding Change Map in Janus Global Life Sciences J Fund (JAGLX)

  

Related books and products to Janus Global Life Sciences J Fund (JAGLX)

  

Latest News on Janus Global Life Sciences J (JAGLX)

See what is happening with Janus Global Life Sciences J Fund (JAGLX)

 

Books and Resources

 

 

See more information on Janus Global Life Sciences J Fund (JAGLX)